Status:
COMPLETED
Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation
Lead Sponsor:
University of Alberta
Conditions:
Kidney Transplant
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Varicella zoster virus is part of the herpesvirus group and causes chickenpox in exposed individuals. The majority of the population is seropositive for this virus. Reactivation of varicella zoster vi...
Eligibility Criteria
Inclusion
- Age 18-65 years
- Listed or will likely be listed for live donor kidney transplant within one month
Exclusion
- 1\. Previous receipt of Zostavax
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 23 2013
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00940940
Start Date
October 1 2009
End Date
September 23 2013
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada